Clozapine : 1994. Symposium. Garden City NY USA, 1994/02/25.
A pharmacoeconomic analysis of clozapine is of particular importance because clozapine has a unique profile of benefits, risks, and costs relative to typical neuroleptic drugs and because it is currently approved for use in only two populations, i.e., neuroleptic-resistant and neuroleptic-intolerant schizophrenic patients, although it has also been found to be useful in a variety of other indications, e.g.. refractory bipolar patients.
The three studies of the primary data relevant to a pharmacoeconomic analysis of clozapine in the treatment of schizophrenia were reviewed.
Mots-clés Pascal : Clozapine, Neuroleptique, Psychotrope, Chimiothérapie, Traitement, Analyse coût, Economie santé, Prévention, Hospitalisation, Homme
Mots-clés Pascal anglais : Neuroleptic, Psychotropic, Chemotherapy, Treatment, Cost analysis, Health economy, Prevention, Hospitalization, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0019831
Code Inist : 002B02B03. Création : 09/06/1995.